Study of Immune Response Monitoring in Adults with Mold Invasive Fungal Infections to Identify Candidates for Immunotherapy

What this Trial Is About

Researchers are studying mold invasive fungal infections, which can be deadly even with the best antifungal treatments. This research focuses on how immune checkpoint inhibitors, originally developed for cancer, might help restore the immune systems ability to fight these infections. The study aims to monitor the immune response, especially the markers on T cells, to find which patients might benefit from adding immunotherapy and the best time to start it. The study includes adult patients diagnosed with mold invasive fungal infections like aspergillosis, mucormycosis, fusariosis, or scedosporiosis, either newly diagnosed or not responding to standard antifungal treatment. Researchers will measure immune checkpoint markers on T cells and monocytes at enrollment, day 14, and week 6. For patients with aspergillosis or mucormycosis, they will also assess specific T cell functions, including cytokine production and proliferation, with and without an anti-PD1 antibody, at enrollment and week 6. Participants will undergo blood tests at these time points to evaluate their immune responses using flow cytometry and FLUOROSPOT assays. The study will correlate immune data with patients underlying conditions, infection types, treatments, and outcomes. This detailed monitoring will help guide when and for whom immunotherapy might be added to antifungal treatment. The study is expected to continue until 2027, and participants will be followed closely throughout the study period.

Immunomonitoring of Mold Invasive Infections